Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Weidinger

Showing results (161-170 of 274) with videos related to

Pageof 28
Sort By:
The Journal of Investigative Dermatology|June 1, 2017
The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy RegistriesPhyllis I Spuls, Louise A A Gerbens, Christian J Apfelbacher, et al.
Experimental Dermatology|May 20, 2016
A novel molecular disease classifier for psoriasis and eczemaNatalie Garzorz-Stark, Linda Krause, Felix Lauffer, et al.
Scientific Reports|February 8, 2020
Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependentlySophia Bergmann, Barbara von Buenau, Sabine Vidal-Y-Sy, et al.
Acta Dermato-Venereologica|March 28, 2009
Lack of association between neuropeptide S receptor 1 gene (NPSR1) and eczema in five European populationsElisabeth Ekelund, Maria Bradley, Stephan Weidinger, et al.
The British Journal of Dermatology|December 2, 2025
The inflammatory skin disease map: an interactive computational resource focused on psoriasis and atopic dermatitis molecular mechanismsMarcio L Acencio, Oxana Lopata, Ahmed A Hemedan, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
Dermatology and Therapy|June 15, 2023
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 StudyAmy S Paller, Carsten Flohr, Lawrence F Eichenfield, et al.
Nature Communications|October 19, 2022
Host genetic factors related to innate immunity, environmental sensing and cellular functions are associated with human skin microbiotaLucas Moitinho-Silva, Frauke Degenhardt, Elke Rodriguez, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|September 17, 2014
Allergy and asthma prevention 2014Antonio Nieto, Ulrich Wahn, Albrecht Bufe, et al.
Pageof 28

Showing results (161-170 of 274) with videos related to

Sort By:
Pageof 28
The Journal of Investigative Dermatology|June 1, 2017
The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy RegistriesPhyllis I Spuls, Louise A A Gerbens, Christian J Apfelbacher, et al.
Experimental Dermatology|May 20, 2016
A novel molecular disease classifier for psoriasis and eczemaNatalie Garzorz-Stark, Linda Krause, Felix Lauffer, et al.
Scientific Reports|February 8, 2020
Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependentlySophia Bergmann, Barbara von Buenau, Sabine Vidal-Y-Sy, et al.
Acta Dermato-Venereologica|March 28, 2009
Lack of association between neuropeptide S receptor 1 gene (NPSR1) and eczema in five European populationsElisabeth Ekelund, Maria Bradley, Stephan Weidinger, et al.
The British Journal of Dermatology|December 2, 2025
The inflammatory skin disease map: an interactive computational resource focused on psoriasis and atopic dermatitis molecular mechanismsMarcio L Acencio, Oxana Lopata, Ahmed A Hemedan, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Dermatology and Therapy|June 23, 2025
Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Stephan Weidinger, Eric L Simpson, et al.
Dermatology and Therapy|June 15, 2023
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 StudyAmy S Paller, Carsten Flohr, Lawrence F Eichenfield, et al.
Nature Communications|October 19, 2022
Host genetic factors related to innate immunity, environmental sensing and cellular functions are associated with human skin microbiotaLucas Moitinho-Silva, Frauke Degenhardt, Elke Rodriguez, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|September 17, 2014
Allergy and asthma prevention 2014Antonio Nieto, Ulrich Wahn, Albrecht Bufe, et al.
Pageof 28